If you’re new to the Journey Medical ($DERM) story, here’s the setup:Journey is a commercial-stage dermatology company with a portfolio of FDA-approved prescription products and a lean, break-even base business. But the spotlight is firmly on Emrosi — a new oral treatment for rosacea, and the first entrant in its category in over 20 years. It launched in April 2025 and has demonstrated superiority over the current standard of care, Oracea. All eyes are now on how the ramp plays out.I’ve been tracking Journey since Emrosi’s FDA approval on November 4, 2024, and first wrote about it here in February. It’s already up ~60% since then — but in my view, the story is just beginning.CEO and Co-Founder Claude Maraoui spent 22 years at Medicis, the dermatology company acquired by Valeant for $2.6B. He was one of the earliest employees there and saw the entire ride. Now, he’s running the same playbook — with many of the same people. Much of Journey’s executive and sales team came over from Medicis, bringing deep category knowledge and a proven commercialization engine.Earlier this week, I finally got on a call with Claude. We went deep: early script momentum, payer traction, manufacturing setup, margin structure, capital runway, and what scaling looks like from here.What follows is a full rundown of that conversation.“There’s No Gamble Here — We’ve Built This Before.”Claude got right to the point: this isn’t his first time commercializing a dermatology brand.“I was one of the first employees at Medicis… 22 years there. We sold it for $2.6 billion. And I brought the same core people over to Journey — executive team, sales force, all of it.”Journey’s base business — which includes legacy products like Qbrexza (hyperhidrosis) and Accutane (cystic acne) — already brings in ~$55M+ annually. The company has 35 reps in the field and is at or near break-even before layering in Emrosi.“We’re already break-even with the base business. Emrosi expenses are new — but everything else is already in place. That’s why Emrosi drops straight to the bottom line.”Early Prescription Traction — and a $20M+ Run Rate AlreadyThree months into launch, Emrosi is already moving.“We’re doing well over 1,000 prescriptions per week. We’ve got well over 1,000 unique prescribers. That number is growing.”Quick math:WAC = $1,298 per 30-capsule scriptGross-to-net = ~70% (i.e., 30% net realization)ASP = ~$390Weekly net revenue = 1,000 TRx × $390 = $390,000Annualized run rate = ~$20M+That’s before any refill velocity, deeper penetration, or acceleration in prescribing volume — and well before full payer coverage.“This is not a hockey-stick launch. We expect a steady, durable ramp over two years. More prescribers, more refills, more coverage.”Gross-to-net will bounce around early on, with copay support, coupon usage, and rebate dynamics still normalizing. But management expects this to stabilize in the 5–6 quarter range.“We’re playing with seven or eight levers — coupons, managed care, reserves, etc. ASP will find its footing as payer mix settles and coverage improves.”And critically, the base business is already covering fixed costs.“We’re already break-even. So the revenue from Emrosi is highly accretive — it drops to the bottom line.”Gross margins in Q1 were ~64%, and management expects that to improve as Emrosi mix increases and early launch costs fade.“We’re not giving specific guidance, but gross margins should continue to rise through 2025.”Sizing the Prize: $200M+ U.S. OpportunityClaude made it clear: this is just the beginning.“We see peak U.S. sales of $200M+ for Emrosi. And we’ve already built the infrastructure to handle that scale.”At a $390 ASP, that implies ~500K annual prescriptions — roughly 10x today’s weekly volume. With strong early uptake, refills building, and payer access improving, the trajectory feels achievable.To put that in context, here’s how Oracea ramped over time — a branded oral rosacea drug with a similar profile:Coverage Expanding Fast — With More to ComePayer traction has been stronger than most new dermatology launches. As of the latest update, Journey has secured access for 65% of U.S. commercial lives, with two of the three major PBMs onboard.“We’ve got over 100 million lives covered already. That number will continue to grow through year-end.”Coverage progress is a key reason the early TRx ramp looks durable — and why management expects ASP to improve over time.Manufacturing Is Secured — Dual-Site SetupEmrosi is manufactured via a dual-site strategy: one facility in India (via Dr. Reddy’s) and a second in Wisconsin, which was onboarded ahead of launch.“Inventory is in place. We’re the only product in our portfolio with two manufacturers — we didn’t want to take any chances.”Management also noted no further regulatory milestone payments are due to Dr. Reddy. Future payments are tied to sales thresholds well beyond near-term expectations.“We’ve paid about $28 million to date. Additional milestones only kick in at much higher revenue — and not for another 18 to 24 months.”Cash Burn and Capital PositionAs of Q1, Journey reported $21 million in cash. Management was clear: no plans for near-term capital raise, and the company expects to turn cash flow positive in 2025.“Our balance sheet is solid. Burn will be minimal, and Emrosi is what gets us to cash flow positive.”Debt is held via SWK — flexible, with prepayment options, and not a near-term concern.“We’ve got flexibility on structure and timing. If rates come down, we’ll look at refinancing — but we’re not under pressure.”Building the Commercial FlywheelOne thing that stood out on the call: Journey isn’t trying to reinvent its model with every launch. It’s running the same commercial playbook that worked at Medicis — and it’s designed to scale.“We average one new product every 18 to 24 months. Emrosi is just the latest.”Their 35-rep sales force is fully deployed and familiar with the category. So as new brands are layered in — whether internally developed or in-licensed — they can slot in with little incremental cost.The company is tightly aligned around performance. Everyone at Journey, including the sales team, has equity. That starts at the top: Claude personally owns close to 10% of the company.“We’re a pay-for-performance company. Everyone at Journey, from sales to HQ, has equity. That alignment is intentional.”Licensing Optionality, Global Rights, and What's NextJourney owns global rights to Emrosi, excluding BRIC countries. Claude confirmed they are actively exploring ex-U.S. partnerships for Emrosi and other products.“We’ve had good conversations in Europe and Latin America. We want to grow organically in the U.S. — but out-license internationally where it makes sense.”No near-term R&D is planned, but they continue to evaluate assets that fit the commercial engine.“We’re looking for the next Emrosi. Something meaningful — not just filler.”What Keeps Him Up at Night?I ask every CEO this question. Claude didn’t flinch.“Last year it was: will we get approval? Then: will we have supply? Now, it’s all about execution.”With FDA approval behind them, and manufacturing up and running, the focus now is consistent delivery. Final ReflectionJourney checks a lot of the right boxes:Proven leadershipCategory focusCommercial disciplineA breakout product with strong early uptakeBut this is still early innings. The next few quarters will tell us a lot about the stickiness of Emrosi demand, the refill curve, and how fast payer traction converts into scripts and ASP expansion.Q2 earnings in August should give the next checkpoint. This isn’t a binary setup — it’s a story about execution. And so far, they’re doing exactly what they said they would.Disclaimer:This is not financial advice. I hold what I write about — but I’ve learned the hard way that being early and being wrong can look a lot alike. Do your own homework. All opinions are my own. I haven’t been compensated by any company to write this.Thanks for reading The 10x Radar! Subscribe for free to receive new posts and support my work.